Edgewise: breaking away from dystrophin for muscular dystrophy
Edgewise emerges from stealth with $50M series B, dystrophin-independent muscle-stabilizing compounds
With a lead compound that staves off use-induced muscle damage, Edgewise thinks it can compete with dystrophin replacement therapies for muscular dystrophy.
Edgewise Therapeutics emerged from stealth this month with a $50 million series B round co-led by Novo Holdings A/S and U.S. Venture Partners and a portfolio of internally developed small molecule therapies for musculoskeletal indications including Duchenne and Becker muscular dystrophy.
Cure Duchenne Ventures, Deerfield Management, New Leaf Venture Partners and founding investor OrbiMed Advisors also participated